|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sedation in gastrointestinal endoscopy: Current issues显示文摘Diagnostic and therapeutic endoscopy can successfully be performed by applying moderate(conscious) sedation.Moderate sedation,using midazolam and an opioid,is the standard method of sedation,although propofol is increasingly being used in many countries because the satisfaction of endoscopists with propofol sedation is greater compared with their satisfaction with conventional sedation.Moreover,the use of propofol is currently preferred for the endoscopic sedation of patients with advanced liver disease due to its short biologic half-life and,consequently,its low risk of inducing hepatic encephalopathy.In the future,propofol could become the preferred sedation agent,especially for routine colonoscopy.Midazolam is the benzodiazepine of choice because of its shorter duration of action and better pharmacokinetic profile compared with diazepam.Among opioids,pethidine and fentanyl are the most popular.A number of other substances have been tested in several clinical trials with promising results.Among them,newer opioids,such as remifentanil,enable a faster recovery.The controversy regarding the administration of sedation by an endoscopist or an experienced nurse,as well as the optimal staffing of en-doscopy units,continues to be a matter of discussion.Safe sedation in special clinical circumstances,such as in the cases of obese,pregnant,and elderly individuals,as well as patients with chronic lung,renal or liver disease,requires modification of the dose of the drugs used for sedation.In the great majority of patients,sedation under the supervision of a properly trained endoscopist remains the standard practice worldwide.In this review,an overview of the current knowledge concerning sedation during digestive endoscopy will be provided based on the data in the current literature. | John K Triantafillidis Emmanuel Merikas Dimitrios Nikolakis Apostolos E Papalois | 2013 | World Journal of Gastroenterology2013，19，4： | 35 |
| 2 | Chios mastic treatment of patients with active Crohn's disease显示文摘AIM: To evaluate the effectiveness of mastic administra-tion on the clinical course and plasma inflammatory me-diators of patients with active Crohn’s disease (CD).METHODS: This pilot study was conducted in patients with established mild to moderately active CD, attend-ing the outpatient clinics of the hospital, and in healthy controls. Ten patients and 8 controls were recruited for a 4-wk treatment with mastic caps (6 caps/d, 0.37 g/cap). All patients successfully completed the protocol. CD Ac-tivity Index (CDAI), Nutritional Risk Index (NRI), C-re-active protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1), and total antioxidant potential (TAP) were evaluated in the plasma at baseline and at the end of the treatment period. Results were expressed as mean values ± SE and P < 0.05 was considered to indicate statistical significance.RESULTS: Patients exhibited significant reduction of CDAI (222.9 ± 18.7 vs 136.3 ± 12.3, P = 0.05) as com-pared to pretreament values. Plasma IL-6 was signifi-cantly decreased (21.2 ± 9.3 pg/mL vs 7.2 ± 2.8 pg/ mL, P = 0.027), and so did CRP (40.3 ± 13.1 mg/mL vs 19.7 ± 5.5, P = 0.028). TAP was significantly increased (0.15 ± 0.09 vs 0.57 ± 0.15 mmol/L uric acid, P = 0.036). No patient or control exhibited any kind of side effects. CONCLUSION: The results suggest that mastic signifi-cantly decreased the activity index and the plasma levels of IL-6 and CRP in patients with mildly to moderately ac-tive CD. Further double-blind, placebo-controlled studies in a larger number of patients are required to clarify the role of this natural product in the treatment of patients with CD. | Andriana C Kaliora Maria G Stathopoulou John K Triantafillidis George VZ Dedoussis Nikolaos K Andrikopoulos | 2007 | World Journal of Gastroenterology2007，13，5： | 7 |
| 3 | Favorable response to subcutaneous administration of infliximab in rats with experimental colitis显示文摘AIM: To investigate the influence of infliximab (Remicade)on experimental colitis produced by 2,4,6,trinitrobenzene sulfonic acid (TNBS) in rats.METHODS: Thirty-six Wistar rats were allocated into four groups (three groups of six animals each and a fourth of 12 animals). Six more healthy animals served as normal controls (Group 5). Group 1:colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol and infliximab was subcutaneously administered at a dose of 5 mg/kg BW; Group 2: colitis was induced and infliximab was subcutaneously administered at a dose of 10 mg/kg BW; Group 3: colitis was induced and infliximab was subcutaneously administered at a dose of 15 mg/kg BW; Group 4: colitis was induced without treatment with infliximab. Infliximab was administered on d 2-6. On the 7th d, all animals were killed. The colon was fixed in 10%buffered formalin and examined by light microscopy for the presence and activity of colitis and the extent of tissue damage. Tumor necrosis factor-alpha (TNF-α) and malondialdehyde (MDA) were also measured.RESULTS: Significant differences concerning the presence of reparable lesions and the extent of bowel mucosa without active inflammation in all groups of animals treated with infliximab compared with controls were found. Significant reduction of the tissue levels of TNF-α in all groups of treated animals as compared withthe untreated ones was found (0.47±0.44, 1.09±0.86,0.43±0.31 vs 18.73±10.53 respectively). Significant reduction in the tissue levels of MDA was noticed in group 1 as compared to group 4, as well as between groups 2 and 4.CONCLUSION: Subcutaneous administration of infliximab reduces the inflammatory activity as well as tissue TNF-α and MDA levels in chemical colitis in rats.Infliximab at a dose of 5 mg/kg BW achieves better histological results and produces higher reduction of the levels of TNF-α than at a dose of 10 mg/kg BW.Infliximab at a dose of 5 mg/kg BW produces higher reduction of tissue MDA levels than at a dose of 15 mg/kg BW. | John K Triantafillidis Apostolos E Papalois Aikaterini Parasi Emmanuel Anagnostakis Stavros Burnazos Aristofanis Gikas Emmanuel G Merikas Emmanuel Douzinas Maria Karagianni Helen Sotiriou | 2005 | World Journal of Gastroenterology2005，11，43： | 5 |
| 4 | Autopsy findings from 111 deaths in the 1999 Athens earthquake as a basis for auditing the emergency response显示文摘 | Papadopoulos IN Kanakaris N Triantafillidis A | 2004 | Br J Surg2004，91，12： | 1 |
| 5 | Clinical patterns of Crohn's disease in Greece: a follow-up study of 155 cases显示文摘 | EMMANOUILIDIS A MANOUSOS O | 2000 | Digestion2000，61，2： | 1 |
| 6 | The role of total parenteral nutrition in inflammatory bowel disease: current aspects显示文摘 | John K. Triantafillidis Apostolos E. Papalois | 2013 | Scandinavian Journal of Gastroenterology2013，，1： | 1 |
| 7 | Increased fasting serum levels of growth hormone and gastrin in patients with gastric and large bowel cancer显示文摘 | Triantafillidis JK Merikas E Govosdis V | 2003 | Hepatogastroentero2003，50，2： | 1 |
| 8 | Homostructured mixed inorganic-organic ion clays:a new approach to epoxy polymer-exfoliated clay nanocomposites with a reduced organic modifier content显示文摘 | Costas S Triantafillidis Peter C LeBaron Thomas J Pinnavaia | 2002 | Chem Mater2002，14，： | 1 |
| 9 | Current and emerging drugs for the treatment of inflammatory bowel disase显示文摘 | Triantafillidis JK Merikas E Georgopoulos F | | 0，，： | 1 |
| 10 | Ulcerative colitis in the elderly:clinical patterns and outcome in 51 Greek patients显示文摘 | Triantafillidis JK Emmanouilidis A Pomonis E | | 0，，5： | 1 |
| 11 | Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review 显示文摘 | Triantafillidis JK Malgarinos G | 2014 | Clin Exp Gastroenterol2014，7，： | 1 |
| 12 | The Role of Enteral Nutrition in Patients with Inflammatory Bowel Disease: Current Aspects显示文摘 | John K. Triantafillidis Costas Vagianos Apostolos E. Papalois Demosthenes Bouros | 2015 | BioMed Research International2015，，： | 1 |
| 13 | Homostructured mixed inorganic-organic ion clays : a new approach to epoxy polymer-exfoliated clay nanocomposites with a reduced organic modifier content显示文摘 | Triantafillidis C S LeBaron P C Pinnavaia T J | 2002 | Chem Mater(S0897-4756)2002，14，10： | 1 |
| 14 | Dealuminated H-Y zeolites: Influence of the degree and the type of dealumination method on the structural and acidic characteristics of H-Y zeolites显示文摘 | Triantafillidis C S Vlessidis A G Evmiridis N P | 2000 | Ind Eng Chem Res2000，39，2： | 1 |
| 15 | Defense mechanisms in inflammatory bowel disease显示文摘 | Thomas N. Hyphantis John K. Triantafillidis Sofia Pappa Christos Mantas Anna Kaltsouda Peter Cherakakis Yannis Alamanos Orestis N. Manousos Venetsanos G. Mavreas | 2005 | Journal of Gastroenterology2005，，1： | 1 |
| 16 | Should hot biopsy forceps be abandoned for polypectomy of diminutive colorectal polyps?显示文摘Standardized approach to polypectomy of diminutive colorectal polyps(DCPs) is lacking since cold biopsy forceps have been associated with high levels of recurrence, hot biopsy forceps are considered inadequate and risky and cold snaring is currently under investigation for its efficacy and safety. This has led to confusion and a gap in clinical practice. This article discusses the usefulness and contemporary practical applicability of hot biopsy forceps and provides wellintentioned criticism of the new European guidelines for the treatment of DCPs. Diminutive colorectal polyps are a source of frustration for the endoscopist since their small size is accompanied by a considerable risk of premalignant neoplasia and a small but nonnegligible risk of advanced neoplasia and even cancer. Since the proportion of diminutive colorectal polyps is substantial and exceeds that of larger polyps, their effective removal poses a considerable workload and a therapeutic challenge. During the last decade, the introduction of cold snaring to routine endoscopy practice has attempted to overcome the use of prior techniques, such as hot biopsy forceps. It is important to recognize that with the exception of endoscopic methods that are obviously unsafe and inadequate to serve their purpose, all other interventional endoscopic methods are operator-dependent in the sense that specific expertise and training are obligatory for the success of any therapeutic intervention. Since relevant publications on hot biopsy forceps are still in favor of its careful use, as it has not yet demonstrated inferiority compared with newer techniques, it would be prudent for any medical practitioner to evaluate the available tools and judge any new proposed technique based on the evidence before it is adopted. | Vasileios Panteris Antonios Vezakis Jk Triantafillidis | 2018 | World Journal of Gastroenterology2018，24，14： | 1 |
| 17 | Effect of the degree and type of the dealumination method on the structural, compositional and acidic characteristics of H-ZSM-5 zeolites 显示文摘 | TRIANTAFILLIDIS C S VLESSIDIS A G NALBANDIAN L | 2001 | Micropor Mesopor Mater2001，47，： | 1 |
| 18 | Ulcerative colitis in the elderly:Clinical patterns and outcome in 51 Greek patients显示文摘 | Triantafillidis JK Emmanouilidis A Pomonis E | 2001 | J Gastroenterol2001，36，： | 1 |
| 19 | Colorectal cancer and inflammatory bowel disease:epidemiology,risk factors,mechanisms of carcinogenesis and prevention strategies显示文摘 | Triantafillidis JK Nasioulas G Kosmidis PA | 2009 | Antieancer Res2009，29，7： | 1 |
| 20 | Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (II)显示文摘 | Laurence Egan Renata D’Inca Tine Jess Gianluca Pellino Franck Carbonnel Bernd Bokemeyer Marcus Harbord Paula Nunes Janneke Van der Woude Francesco Selvaggi John Triantafillidis | 2014 | Journal of Crohn’s and Colitis2014，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员